UNIVERSITY OF ALABAMA HOSPITAL
- Type
- Teaching hospital
- Where
- BIRMINGHAM, AL
- Medicare CCN
- 010033
- Received
- $33,886,951 in 3,184 records, 2019 ($2,396,462 general, $31,490,489 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit contractor: UNIVERSITY OF ALABAMA HOSPITAL Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2019 | General payment | 509 | $2,396,462 |
| 2019 | Research payment | 2,675 | $31,490,489 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 2,675 | $31,490,489 |
| Grant | 54 | $1,108,405 |
| Space rental or facility fees (teaching hospital only) | 323 | $352,900 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 50 | $274,860 |
| Charitable Contribution | 15 | $236,883 |
| Consulting Fee | 12 | $189,350 |
| Education | 38 | $159,756 |
| Royalty or License | 1 | $46,837 |
| Gift | 7 | $22,337 |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing | 3 | $4,500 |
| Food and Beverage | 6 | $630 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2019-12-31 | Gilead Sciences, Inc. | $417,795 | Grant | Cash or cash equivalent | 2019 | ||
| 2019-12-31 | Intuitive Surgical, Inc. | $52,320 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2019 | |
| 2019-12-31 | AstraZeneca UK Limited | $15,915 | Research payment | In-kind items and services | The purpose of this study is to characterise longterm safety and tolerability of intravenous anifrolumab A Multicentre R | 2019 | |
| 2019-12-31 | AngioDynamics, Inc. | $13,000 | Education | In-kind items and services | Solero Device, Oncology Surgery | 2019 | |
| 2019-12-31 | AngioDynamics, Inc. | $13,000 | Education | In-kind items and services | Solero Device, Oncology Surgery | 2019 | |
| 2019-12-31 | Allergan, Inc. | $11,576 | Research payment | Cash or cash equivalent | BOTOX COSMETIC Biological | A Study Evaluating the Efficacy and Safety of BOTOX Intravesical Instillation in Patients with Overactive Bladder and Ur | 2019 |
| 2019-12-31 | Intuitive Surgical, Inc. | $10,720 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2019 | |
| 2019-12-31 | Renovia Inc | $10,639 | Research payment | Cash or cash equivalent | Leva Pelvic Floor Trainer Device, Urology | Use of the Leva Pelvic Digital Health System in Women With Fecal Incontinence a Pilot Study | 2019 |
| 2019-12-31 | Intuitive Surgical, Inc. | $10,000 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2019 | |
| 2019-12-31 | Allergan, Inc. | $9,873 | Research payment | Cash or cash equivalent | A 52-Week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo and Active-Controlled, Operationally Seamless Ph | 2019 | |
| 2019-12-31 | Stryker Corporation | $5,272 | Gift | Cash or cash equivalent | NONE Device, NONE | 2019 | |
| 2019-12-31 | Roche Diagnostics Corporation | $3,333 | Education | In-kind items and services | DIS Navify Software Device, Diagnostic Information Solutions | 2019 | |
| 2019-12-31 | AstraZeneca Pharmaceuticals LP | $3,272 | Research payment | In-kind items and services | IMFINZI Drug, Oncology | A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with | 2019 |
| 2019-12-31 | AstraZeneca UK Limited | $2,758 | Research payment | In-kind items and services | EPANOVA Drug, Cardiovascular and Metabolism | A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs wi | 2019 |
| 2019-12-31 | AstraZeneca Pharmaceuticals LP | $2,674 | Research payment | In-kind items and services | IMFINZI Drug, Oncology | A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Co | 2019 |
| 2019-12-31 | Allergan, Inc. | $2,010 | Research payment | Cash or cash equivalent | A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamoreli | 2019 | |
| 2019-12-31 | Allergan, Inc. | $1,894 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Placebo-controlled, Multicenter, Efficacy and Safety Study of Rapastinel for Rapid Treatment | 2019 | |
| 2019-12-31 | Cook Incorporated | $1,400 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2019 | ||
| 2019-12-31 | AstraZeneca UK Limited | $668 | Research payment | In-kind items and services | IMFINZI Drug, Oncology | A Phase II, Multi-Center, Single-Arm, Global Study of MEDI4736 Monotherapy in Patients With Recurrent or Metastatic Squa | 2019 |
| 2019-12-31 | AstraZeneca Pharmaceuticals LP | $561 | Research payment | In-kind items and services | EPANOVA Drug, Cardiovascular and Metabolism | A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs wi | 2019 |
| 2019-12-31 | AstraZeneca UK Limited | $277 | Research payment | In-kind items and services | IMFINZI Drug, Oncology | A Phase II Randomized Open Label Multi Center Global Study of MEDI4736 Monotherapy Tremelimumab Monotherapy and MEDI4736 | 2019 |
| 2019-12-31 | Siemens Medical Solutions USA, Inc. | $240 | Research payment | Cash or cash equivalent | UAlabama2019MRIPR1058IPR1084Kim | 2019 | |
| 2019-12-31 | Allergan, Inc. | $110 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION | 2019 | |
| 2019-12-31 | Stryker Corporation | $48 | Gift | In-kind items and services | AXS UNIVERSAL Device, ASPIRATION | 2019 | |
| 2019-12-31 | AstraZeneca Pharmaceuticals LP | $11 | Research payment | In-kind items and services | LYNPARZA Drug, Oncology | This is a non randomized open label study to assess olaparib tablets as a treatment for subjects with different homologo | 2019 |
| 2019-12-31 | AstraZeneca UK Limited | $9 | Research payment | In-kind items and services | LYNPARZA Drug, Oncology | Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene BRCA Mutated Ovarian Cancer Patients Who Have | 2019 |
| 2019-12-30 | ROCHE MOLECULAR SYSTEMS, INC. | $17,103 | Research payment | In-kind items and services | COBAS INSTRUMENTS & REAGENTS Device, Molecular Diagnostics | RD003542 | 2019 |
| 2019-12-30 | ABBVIE INC. | $12,351 | Research payment | Cash or cash equivalent | M15-741 | 2019 | |
| 2019-12-30 | ABBVIE INC. | $6,560 | Research payment | Cash or cash equivalent | M16-824 | 2019 | |
| 2019-12-30 | ROCHE MOLECULAR SYSTEMS, INC. | $4,208 | Research payment | In-kind items and services | COBAS INSTRUMENTS & REAGENTS Device, Molecular Diagnostics | RD003542 | 2019 |
| 2019-12-30 | ABBVIE INC. | $3,250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Mavyret Drug, Virology | 2019 | |
| 2019-12-30 | Otsuka Pharmaceutical Co., Ltd. | $1,746 | Research payment | Cash or cash equivalent | A RANDOMIZED, OPEN-LABEL, PHASE 1-2 STUDY OF ASTX727 LOW DOSE ASTX727 LD EXTENDED SCHEDULE IN SUBJECTS WITH LOWER RISK I | 2019 | |
| 2019-12-30 | ROCHE MOLECULAR SYSTEMS, INC. | $1,692 | Research payment | In-kind items and services | COBAS INSTRUMENTS & REAGENTS Device, Molecular Diagnostics | RD003542 | 2019 |
| 2019-12-30 | ROCHE MOLECULAR SYSTEMS, INC. | $285 | Research payment | In-kind items and services | COBAS INSTRUMENTS & REAGENTS Device, Molecular Diagnostics | RD003542 | 2019 |
| 2019-12-30 | Radius Health, Inc. | $62 | Research payment | In-kind items and services | A RANDOMIZED, NON-INFERIORITY, PHASE 3, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABALOPARATI | 2019 | |
| 2019-12-30 | Radius Health, Inc. | $15 | Research payment | In-kind items and services | A RANDOMIZED, NON-INFERIORITY, PHASE 3, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABALOPARATI | 2019 | |
| 2019-12-27 | Abbott Laboratories | $115,811 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | M2000 system Device, Molecular Diagnostics | 2019 | |
| 2019-12-26 | Medical Device Business Services, Inc. | $9,920 | Research payment | Cash or cash equivalent | Visitag Device, Cardiology | Evaluation of Visitag Surpoint Module with External Processing Unit when used with the Thermocool Smarttouch SF and Ther | 2019 |
| 2019-12-26 | Gen-Probe, Inc. | $6,320 | Research payment | Cash or cash equivalent | Mycoplasma genitalium Device, Diagnostics | Mycoplasma genitalium prevalence project | 2019 |
| 2019-12-26 | United Therapeutics Corporation | $898 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | AN OPEN-LABEL EXTENSION STUDY OF INHALED TREPROSTINIL IN SUBJECTS WITH PULMONARY HYPERTENSION DUE TO PARENCHYMAL LUNG DI | 2019 |
| 2019-12-26 | United Therapeutics Corporation | $168 | Research payment | Cash or cash equivalent | NONE Drug, NON-BRANDEDDISEASE STATE | Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso | 2019 |
| 2019-12-26 | United Therapeutics Corporation | $142 | Research payment | Cash or cash equivalent | NONE Drug, NON-BRANDEDDISEASE STATE | Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso | 2019 |
| 2019-12-24 | Amgen Inc. | $2,565 | Research payment | Cash or cash equivalent | Repatha Biological, Cardiology | FOURIER OLE (Ph 4) | 2019 |
| 2019-12-24 | Allergan, Inc. | $1,510 | Research payment | Cash or cash equivalent | BOTOX Drug, UROLOGY | A PHASE 2, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE TREATMENT, 2-STAGE, DOSE FINDING STUDY EVA | 2019 |
| 2019-12-24 | PFIZER INC. | $305 | Research payment | Cash or cash equivalent | AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY AND EFFICACY OF PF04965842 IN ADULT PATIENTS WITH MODERATETOS | 2019 | |
| 2019-12-24 | Amgen Inc. | $284 | Research payment | Cash or cash equivalent | IMLYGIC Biological, Oncology | P2 Neo-adjuvant melanoma | 2019 |
| 2019-12-24 | Allergan, Inc. | $200 | Research payment | Cash or cash equivalent | BOTOX Drug, UROLOGY | A PHASE 2, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE TREATMENT, 2-STAGE, DOSE FINDING STUDY EVA | 2019 |
| 2019-12-23 | EMD Serono, Inc. | $81,794 | Research payment | Cash or cash equivalent | Effects of Exercise Training on Learning and Memory Outcomes in MS | 2019 | |
| 2019-12-23 | Genentech, Inc. | $74,603 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | PH1B 2 TDB POLA DOSE ESCALATION IN R R NHL PH1B FOLLOWED BY EXPANSION IN R R DLBCL AND R R FL PH2 | 2019 |
| 2019-12-23 | Novartis Pharmaceuticals Corporation | $21,206 | Research payment | Cash or cash equivalent | ADAKVEO Biological, HEMATOLOGY | A PHASE 2 MULTICENTER OPEN LABEL STUDY TO ASSESS APPROPRIATE DOSING AND TO EVALUATE SAFETY OF CRIZANLIZUMAB WITH OR WITH | 2019 |
| 2019-12-23 | Chugai Pharmaceutical Co., Ltd. | $4,760 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | A Multicenter, Randomized, Addition to Baseline Treatment, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate t | 2019 |
| 2019-12-23 | SEAGEN INC. | $4,062 | Research payment | Cash or cash equivalent | A Single Arm, Multicenter, International Trial of Tisotumab Vedotin HuMax-TF-ADC in Previously Treated, Recurrent or Met | 2019 | |
| 2019-12-23 | Janssen Research & Development, LLC | $1,554 | Research payment | Cash or cash equivalent | Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus | 2019 | |
| 2019-12-20 | Navidea Biopharmaceuticals, Inc. | $32,349 | Research payment | Cash or cash equivalent | 2019 | ||
| 2019-12-20 | Janssen Research & Development, LLC | $5,051 | Research payment | Cash or cash equivalent | An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression | 2019 | |
| 2019-12-20 | ABBVIE INC. | $4,057 | Research payment | Cash or cash equivalent | Humira Biological, Immunology | P11-292 | 2019 |
| 2019-12-19 | Amgen Inc. | $162,498 | Research payment | Cash or cash equivalent | UAB Cardiovascular Collaboration Infrastructure 2019 (Cardiovascular Disease, Prevention, Treatment and Outcomes | 2019 | |
| 2019-12-19 | Biogen, Inc. | $35,997 | Research payment | Cash or cash equivalent | AVONEX Biological, NEUROLOGY | GLB-AVX-19-11478 | 2019 |
| 2019-12-19 | Shire North American Group Inc | $25,202 | Research payment | Cash or cash equivalent | CONTINUATION STUDY WITH BUDESONIDE ORAL SUSPENSION BOS FOR ADOLESCENT AND ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS E | 2019 | |
| 2019-12-19 | Janssen Research & Development, LLC | $14,475 | Research payment | Cash or cash equivalent | Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus | 2019 | |
| 2019-12-19 | Incyte Corporation | $8,544 | Research payment | Cash or cash equivalent | An Open Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other M | 2019 | |
| 2019-12-19 | PFIZER INC. | $6,630 | Research payment | Cash or cash equivalent | A PHASE 2 PLACEBOCONTROLLED RANDOMIZED PROOF OF CONCEPT STUDY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT W | 2019 | |
| 2019-12-19 | Novartis Pharmaceuticals Corporation | $5,845 | Research payment | Cash or cash equivalent | ARZERRA Drug, HEMATOLOGY | AN OPEN LABEL SINGLE ARM MULTI CENTER EXTENSION STUDY EVALUATING LONG TERM SAFETY TOLERABILITY AND EFFECTIVENESS OF OFAT | 2019 |
| 2019-12-19 | Tactile Systems Technology Inc | $2,720 | Research payment | Cash or cash equivalent | Device, Flexitouch | Head and Neck Lymphedema Retrospective Chart Review | 2019 |
| 2019-12-19 | Medical Device Business Services, Inc. | $716 | Research payment | Cash or cash equivalent | Evaluation of QDOT MICRO catheter for pulmonary vein isolation in subjects with Paroxysmal Atrial Fibrillation | 2019 | |
| 2019-12-19 | Tetraphase Pharmaceuticals, Inc. | $650 | Education | Cash or cash equivalent | Xerava Drug, Complicated Intra-Abdominal Infections | 2019 | |
| 2019-12-19 | Ipsen Innovation | $315 | Research payment | Cash or cash equivalent | DYSPORT Drug, Neurology | A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And | 2019 |
| 2019-12-19 | Shire North American Group Inc | $78 | Research payment | Cash or cash equivalent | CONTINUATION STUDY WITH BUDESONIDE ORAL SUSPENSION BOS FOR ADOLESCENT AND ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS E | 2019 | |
| 2019-12-19 | Amgen Inc. | $18 | Research payment | In-kind items and services | Otezla Biological, Inflammation | An Efficacy and Safety Study of Apremilast CC-10004 in Subjects With Moderate to Severe Genital Psoriasis DISCREET | 2019 |
| 2019-12-18 | Roche TCRC, Inc. | $24,980 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY IN EARLY STAGE PARKINSON S DISEASE PATIENTS | 2019 |
| 2019-12-18 | Roche TCRC, Inc. | $18,392 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY IN EARLY STAGE PARKINSON S DISEASE PATIENTS | 2019 |
| 2019-12-18 | SEAGEN INC. | $13,973 | Research payment | Cash or cash equivalent | A phase 1, multicenter, open-label, dose-escalation study of SGN 2FF in patients with advanced solid tumors | 2019 | |
| 2019-12-18 | Intercept Pharmaceuticals, Inc. | $12,391 | Research payment | Cash or cash equivalent | 1009742 | 2019 | |
| 2019-12-18 | SEAGEN INC. | $10,036 | Research payment | Cash or cash equivalent | A phase 1, multicenter, open-label, dose-escalation study of SGN 2FF in patients with advanced solid tumors | 2019 | |
| 2019-12-18 | Gilead Sciences, Inc. | $6,014 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena | 2019 |
| 2019-12-18 | Gilead Sciences, Inc. | $4,948 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Tra | 2019 |
| 2019-12-18 | PFIZER INC. | $2,661 | Research payment | Cash or cash equivalent | A PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF06651 | 2019 | |
| 2019-12-17 | ABBVIE INC. | $9,256 | Research payment | Cash or cash equivalent | Skyrizi Biological, Immunology | M15-997 | 2019 |
| 2019-12-17 | Genentech, Inc. | $4,745 | Research payment | Cash or cash equivalent | Drug | TENECTEPLASE IN STROKE PATIENTS BETWEEN 4 5 AND 24 HOURS | 2019 |
| 2019-12-17 | ABBVIE INC. | $4,149 | Research payment | Cash or cash equivalent | Duopa Drug, Neuroscience | P14-494 | 2019 |
| 2019-12-17 | Medical Device Business Services, Inc. | $2,976 | Grant | Cash or cash equivalent | 2019 | ||
| 2019-12-17 | Genentech, Inc. | $887 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PH II PC DRF RCT OF GDC 0853 IN ERL | 2019 |
| 2019-12-17 | Allergan, Inc. | $864 | Research payment | Cash or cash equivalent | AURORA A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of | 2019 | |
| 2019-12-17 | Merck Sharp & Dohme LLC | $402 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | I-SPY 2 Trial Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2 | 2019 |
| 2019-12-17 | Shire North American Group Inc | $374 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2019 |
| 2019-12-16 | Biosense Webster, Inc. | $35,000 | Grant | Cash or cash equivalent | 2019 | ||
| 2019-12-16 | KYOWA KIRIN, INC. | $7,500 | Education | Cash or cash equivalent | NOURIANZ Drug, ADENOSINE A2A RECEPTORS | 2019 | |
| 2019-12-16 | Incyte Corporation | $1,225 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-12-16 | Incyte Corporation | $1,225 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-12-16 | Incyte Corporation | $1,225 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-12-16 | Incyte Corporation | $735 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-12-13 | Allergan, Inc. | $10,165 | Research payment | Cash or cash equivalent | BOTOX COSMETIC Biological | A Study Evaluating the Efficacy and Safety of BOTOX Intravesical Instillation in Patients with Overactive Bladder and Ur | 2019 |
| 2019-12-13 | Janssen Research & Development, LLC | $9,500 | Research payment | Cash or cash equivalent | Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus | 2019 | |
| 2019-12-13 | Clovis Oncology, Inc. | $7,393 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene | 2019 |
| 2019-12-13 | Shire North American Group Inc | $754 | Research payment | Cash or cash equivalent | GATTEX Drug, INTERNAL MEDICINE | A PROSPECTIVE, MULTI-CENTER REGISTRY FOR PATIENTS WITH SHORT BOWEL SYNDROME | 2019 |
| 2019-12-13 | Genentech, Inc. | $750 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PHASE 3 STUDY OF ANTI PDL1 WITH ABRAXANE IN TN MBC | 2019 |
| 2019-12-13 | Shire North American Group Inc | $603 | Research payment | Cash or cash equivalent | GATTEX Drug, INTERNAL MEDICINE | A PROSPECTIVE, MULTI-CENTER REGISTRY FOR PATIENTS WITH SHORT BOWEL SYNDROME | 2019 |
| 2019-12-12 | PFIZER INC. | $892,125 | Research payment | Cash or cash equivalent | PHASE 1B STUDY TO ASSESS THE SAFETY TOLERABILITY AND CLINICAL ACTIVITY OF GEDATOLISIB IN COMBINATION WITH PALBOCICLIB AN | 2019 | |
| 2019-12-12 | PFIZER INC. | $82,542 | Research payment | Cash or cash equivalent | PHASE 1B STUDY TO ASSESS THE SAFETY TOLERABILITY AND CLINICAL ACTIVITY OF GEDATOLISIB IN COMBINATION WITH PALBOCICLIB AN | 2019 | |
| 2019-12-12 | Kite Pharma, Inc. | $29,437 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Thera | 2019 | |
| 2019-12-12 | PFIZER INC. | $27,900 | Research payment | Cash or cash equivalent | PHASE 1B STUDY TO ASSESS THE SAFETY TOLERABILITY AND CLINICAL ACTIVITY OF GEDATOLISIB IN COMBINATION WITH PALBOCICLIB AN | 2019 | |
| 2019-12-12 | Stryker Corporation | $17,500 | Research payment | Cash or cash equivalent | T2 Device, TRAUMA & EXTREMETIES | A RETROSPECTIVE DATA COLLECTION OF THE INTERNAL FRACTURE FIXATION, STABILIZATION AND SUPPORT OF FRACTURES, AND BONE FIXA | 2019 |
| 2019-12-12 | IRONWOOD PHARMACEUTICALS, INC | $12,963 | Research payment | Cash or cash equivalent | IW-3718 | C3718-302 | 2019 |
| 2019-12-12 | PFIZER INC. | $6,420 | Research payment | Cash or cash equivalent | PHASE 1B STUDY TO ASSESS THE SAFETY TOLERABILITY AND CLINICAL ACTIVITY OF GEDATOLISIB IN COMBINATION WITH PALBOCICLIB AN | 2019 | |
| 2019-12-12 | PFIZER INC. | $6,252 | Research payment | Cash or cash equivalent | PHASE 1B STUDY TO ASSESS THE SAFETY TOLERABILITY AND CLINICAL ACTIVITY OF GEDATOLISIB IN COMBINATION WITH PALBOCICLIB AN | 2019 | |
| 2019-12-12 | Henry Schein, Inc. | $5,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DENTSPLY Device, General Dental and Oral Health | 2019 | |
| 2019-12-12 | ABBVIE INC. | $2,600 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Humira Biological, Immunology | 2019 | |
| 2019-12-12 | JAZZ PHARMACEUTICALS INC. | $2,170 | Research payment | Cash or cash equivalent | DEFITELIO Drug, HEMATOLOGY | A PHASE 3, RANDOMIZED, ADAPTIVE STUDY COMPARING THE EFFICACY AND SAFETY OF DEFIBROTIDE VS BEST SUPPORTIVE CARE IN THE PR | 2019 |
| 2019-12-12 | PFIZER INC. | $2,002 | Research payment | Cash or cash equivalent | PHASE 1B STUDY TO ASSESS THE SAFETY TOLERABILITY AND CLINICAL ACTIVITY OF GEDATOLISIB IN COMBINATION WITH PALBOCICLIB AN | 2019 | |
| 2019-12-12 | Incyte Corporation | $1,887 | Research payment | Cash or cash equivalent | An Open Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other M | 2019 | |
| 2019-12-12 | Foundation Medicine, Inc. | $1,275 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | FOUNDATIONONE LIQUID Device, ONCOLOGY | 2019 | |
| 2019-12-12 | Genentech, Inc. | $1,231 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD | 2019 |
| 2019-12-12 | Incyte Corporation | $599 | Research payment | Cash or cash equivalent | An Open Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other M | 2019 | |
| 2019-12-12 | PFIZER INC. | $507 | Research payment | Cash or cash equivalent | PHASE 1B STUDY TO ASSESS THE SAFETY TOLERABILITY AND CLINICAL ACTIVITY OF GEDATOLISIB IN COMBINATION WITH PALBOCICLIB AN | 2019 | |
| 2019-12-12 | Abbott Laboratories | $334 | Research payment | Cash or cash equivalent | Portico Resheathable Transcatheter Aortic Valve System Device, Cardiac Arrhythmias and Heart Failure | Portico Re-sheathable Transcatheter Aortic Valve System US IDE Trial (PORTICO) | 2019 |
| 2019-12-11 | CSL Behring | $44,325 | Research payment | In-kind items and services | Berinert Biological, Immunology | Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Ref | 2019 |
| 2019-12-11 | ABBVIE INC. | $23,658 | Research payment | Cash or cash equivalent | M17-327 | 2019 | |
| 2019-12-11 | Roche TCRC, Inc. | $22,526 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY IN EARLY STAGE PARKINSON S DISEASE PATIENTS | 2019 |
| 2019-12-11 | Incyte Corporation | $14,513 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-12-11 | Intercept Pharmaceuticals, Inc. | $14,016 | Research payment | Cash or cash equivalent | 1009742 | 2019 | |
| 2019-12-11 | Genentech, Inc. | $8,275 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | OPEN LABEL EXTENSION | 2019 |
| 2019-12-11 | Incyte Corporation | $7,050 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose EscalationDose Expansion, Safety and Tolerability Study of INCB057643 in Subjects with Adva | 2019 | |
| 2019-12-11 | United Therapeutics Corporation | $3,538 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | AN OPEN-LABEL EXTENSION STUDY OF INHALED TREPROSTINIL IN SUBJECTS WITH PULMONARY HYPERTENSION DUE TO PARENCHYMAL LUNG DI | 2019 |
| 2019-12-11 | United Therapeutics Corporation | $3,485 | Research payment | Cash or cash equivalent | NONE Drug, NON-BRANDEDDISEASE STATE | Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso | 2019 |
| 2019-12-11 | Ethicon Endo-Surgery Inc. | $3,152 | Research payment | Cash or cash equivalent | ECHELON FLEX Stapler Device, Endo-Mechanical | An Adaptive, Sequential Evaluation of Powered and Manual Circular Staplers in Left-Sided Colorectal Anastomoses (ESC-16- | 2019 |
| 2019-12-11 | Cook Incorporated | $2,500 | Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing | Cash or cash equivalent | Cook Medical Zenith Device, Aortic Intervention | 2019 | |
| 2019-12-11 | SANOFI US SERVICES INC. | $2,325 | Research payment | Cash or cash equivalent | SAR439954 Drug | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotaglif | 2019 |
| 2019-12-11 | GENZYME CORPORATION | $2,100 | Research payment | Cash or cash equivalent | FABRY-DISEASE Drug | Fabry LSD Data Registry | 2019 |
| 2019-12-11 | Cook Incorporated | $1,500 | Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing | Cash or cash equivalent | Cook Medical Peripheral Intervention Device, Peripheral Intervention | 2019 | |
| 2019-12-11 | Stryker Corporation | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | MESA Device, SPINE | 2019 | |
| 2019-12-11 | Roche TCRC, Inc. | $1,420 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY IN EARLY STAGE PARKINSON S DISEASE PATIENTS | 2019 |
| 2019-12-11 | Eli Lilly and Company | $1,124 | Research payment | In-kind items and services | A MULTICENTER, RANDOMIZED, OPEN LABEL, PHASE 3 TRIAL COMPARING SELPERCATINIB TO PHYSICIANS CHOICE OF CABOZANTINIB OR VAN | 2019 | |
| 2019-12-11 | United Therapeutics Corporation | $952 | Research payment | Cash or cash equivalent | TYVASO Drug, PAH | A MULTICENTER RANDOMIZED DOUBLE-BLINDED PLACEBO-CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF INHALED TREPROST | 2019 |
| 2019-12-11 | NEUROPACE, INC. | $851 | Research payment | Cash or cash equivalent | RNS System Device, Epilepsy | Post Approval Study | 2019 |
| 2019-12-10 | ABBVIE INC. | $9,804 | Research payment | Cash or cash equivalent | M17-327 | 2019 | |
| 2019-12-10 | PFIZER INC. | $9,594 | Research payment | Cash or cash equivalent | A PHASE 2A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY WITH AN EXTENSION PERIOD TO EVALUATE THE EFFICACY | 2019 | |
| 2019-12-10 | PFIZER INC. | $8,917 | Research payment | Cash or cash equivalent | A PHASE 2A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY WITH AN EXTENSION PERIOD TO EVALUATE THE EFFICACY | 2019 | |
| 2019-12-10 | ABBVIE INC. | $6,192 | Research payment | Cash or cash equivalent | M17-327 | 2019 | |
| 2019-12-10 | ABBVIE INC. | $5,047 | Research payment | Cash or cash equivalent | M17-327 | 2019 | |
| 2019-12-10 | Baxter Healthcare | $3,465 | Education | Cash or cash equivalent | Renal - Non Product Related Biological, Renal | 2019 | |
| 2019-12-10 | Shire North American Group Inc | $2,162 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2019 |
| 2019-12-10 | Shire North American Group Inc | $2,162 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2019 |
| 2019-12-10 | Lilly USA, LLC | $1,307 | Research payment | Cash or cash equivalent | FORTEO Drug, Bone Muscle Joint | TERIPARATIDE AND RISEDRONATE IN THE TREATMENT OF PATIENTS WITH SEVERE POSTMENOPAUSAL OSTEOPOROSIS - COMPARATIVE EFFECTS | 2019 |
| 2019-12-10 | Shire North American Group Inc | $1,081 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2019 |
| 2019-12-10 | Shire North American Group Inc | $520 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2019 |
| 2019-12-10 | Shire North American Group Inc | $520 | Research payment | Cash or cash equivalent | HYQVIA Biological, IMMUNOLOGY | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2019 |
| 2019-12-10 | ABBVIE INC. | $392 | Research payment | Cash or cash equivalent | M15-741 | 2019 | |
| 2019-12-10 | Ivoclar Vivadent, Inc. | $203 | Research payment | In-kind items and services | ZirCAD Prime strength and translucency | 2019 | |
| 2019-12-10 | ABBVIE INC. | $200 | Research payment | Cash or cash equivalent | M17-327 | 2019 | |
| 2019-12-09 | GENZYME CORPORATION | $50,000 | Research payment | Cash or cash equivalent | AUBAGIO Drug, MULTIPLE SCLEROSIS | Teriflunomide as a disease modifying anti-inflammatory therapy for a severe animal model of chronic inflammatory demyeli | 2019 |
| 2019-12-09 | Baxter Healthcare | $15,000 | Education | Cash or cash equivalent | Renal - Chronic Device, Renal | 2019 | |
| 2019-12-09 | ABBVIE INC. | $3,117 | Research payment | Cash or cash equivalent | Venclexta Drug, Virology | M15-538 | 2019 |
| 2019-12-09 | Dynavax Technologies Corporation | $3,103 | Research payment | Cash or cash equivalent | Intratumoral SD-101 Drug | A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or R | 2019 |
| 2019-12-09 | Bayer Healthcare Pharmaceuticals Inc. | $2,600 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Stivarga Drug, Oncology | 2019 | |
| 2019-12-09 | Incyte Corporation | $85 | Research payment | Cash or cash equivalent | A Double Blind, Randomized, Dose Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo | 2019 | |
| 2019-12-09 | Incyte Corporation | $70 | Research payment | Cash or cash equivalent | A Double Blind, Randomized, Dose Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo | 2019 | |
| 2019-12-09 | Incyte Corporation | $21 | Research payment | Cash or cash equivalent | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2019 | |
| 2019-12-09 | Incyte Corporation | $20 | Research payment | Cash or cash equivalent | A Double Blind, Randomized, Dose Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo | 2019 | |
| 2019-12-09 | Incyte Corporation | $12 | Research payment | Cash or cash equivalent | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2019 | |
| 2019-12-09 | Incyte Corporation | $12 | Research payment | Cash or cash equivalent | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2019 | |
| 2019-12-09 | Incyte Corporation | $12 | Research payment | Cash or cash equivalent | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2019 | |
| 2019-12-09 | Incyte Corporation | $12 | Research payment | Cash or cash equivalent | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2019 | |
| 2019-12-09 | Incyte Corporation | $12 | Research payment | Cash or cash equivalent | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2019 | |
| 2019-12-09 | Incyte Corporation | $10 | Research payment | Cash or cash equivalent | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2019 | |
| 2019-12-09 | Incyte Corporation | $10 | Research payment | Cash or cash equivalent | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2019 | |
| 2019-12-07 | Genentech, Inc. | $62,004 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | ASO HTT PIVOTAL TRIAL | 2019 |
| 2019-12-07 | PFIZER INC. | $4,235 | Research payment | Cash or cash equivalent | AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY AND EFFICACY OF PF04965842 IN ADULT PATIENTS WITH MODERATETOS | 2019 | |
| 2019-12-07 | Genentech, Inc. | $1,337 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | R BENDA CD79B | 2019 |
| 2019-12-06 | GW Research Limited | $32,256 | Research payment | Cash or cash equivalent | GWEP1521 | 2019 | |
| 2019-12-06 | GW Research Limited | $3,150 | Research payment | Cash or cash equivalent | GWEP1521 | 2019 | |
| 2019-12-06 | Allergan, Inc. | $952 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Placebo-controlled, Multicenter, Efficacy and Safety Study of Rapastinel for Rapid Treatment | 2019 | |
| 2019-12-06 | Eisai Inc. | $750 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Fycompa Drug, Neurology | 2019 | |
| 2019-12-06 | Janssen Research & Development, LLC | $117 | Research payment | Cash or cash equivalent | MS PHASE 3 ADD ON HQ - AC-058B302 | 2019 | |
| 2019-12-05 | Genentech, Inc. | $31,913 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD | 2019 |
| 2019-12-05 | Genentech, Inc. | $16,254 | Research payment | Cash or cash equivalent | Zelboraf Biological, BioOncology | VEMURAFENIB COBIMETINIB ATEZOLIZUMAB TRIPLET COMBINATION IN ADVANCED MELANOMA | 2019 |
| 2019-12-05 | PFIZER INC. | $7,956 | Research payment | Cash or cash equivalent | A PHASE 2 PLACEBOCONTROLLED RANDOMIZED PROOF OF CONCEPT STUDY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT W | 2019 | |
| 2019-12-05 | Janssen Research & Development, LLC | $7,693 | Research payment | Cash or cash equivalent | A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus | 2019 | |
| 2019-12-05 | PFIZER INC. | $3,860 | Research payment | Cash or cash equivalent | BAVENCIO Drug, ONCOLOGY | A PHASE 1 PHARMACOKINETICPHARMACODYNAMIC STUDY OF AVELUMAB MSB0010718C IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED STAG | 2019 |
| 2019-12-05 | PFIZER INC. | $2,914 | Research payment | Cash or cash equivalent | A PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF06651 | 2019 | |
| 2019-12-05 | ABBVIE INC. | $2,163 | Research payment | Cash or cash equivalent | M15-741 | 2019 | |
| 2019-12-05 | ABBVIE INC. | $1,806 | Research payment | Cash or cash equivalent | M16-824 | 2019 | |
| 2019-12-05 | HOLOGIC INC | $1,400 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2019 | ||
| 2019-12-05 | Mallinckrodt Enterprises LLC | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ACTHAR Biological, AUTOIMMUNE AND RARE DISEASE | 2019 | |
| 2019-12-05 | SANOFI US SERVICES INC. | $103 | Research payment | Cash or cash equivalent | SOTAGLIFLOZIN Drug | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of | 2019 |
| 2019-12-05 | PFIZER INC. | $36 | Research payment | Cash or cash equivalent | A PHASE 1B OPENLABEL THREEARM MULTICENTER STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF PF05212384 PI3KMTOR INHIBITOR I | 2019 | |
| 2019-12-04 | Alexion Pharmaceuticals, Inc. | $3,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | SOLIRIS Drug, Immunology | 2019 | |
| 2019-12-04 | E.R. Squibb & Sons, L.L.C. | $2,126 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase III Adjuvant Melanoma Stage II B C Opdivo Mono | 2019 |
| 2019-12-04 | Alexion Pharmaceuticals, Inc. | $700 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | SOLIRIS Drug, Immunology | 2019 | |
| 2019-12-03 | Incyte Corporation | $17,379 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-12-03 | Intercept Pharmaceuticals, Inc. | $9,040 | Research payment | Cash or cash equivalent | 1009742 | 2019 | |
| 2019-12-03 | Incyte Corporation | $5,500 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-12-03 | Incyte Corporation | $2,403 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-12-03 | Genentech, Inc. | $1,535 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PHASE 3 STUDY OF ANTI PDL1 WITH ABRAXANE IN TN MBC | 2019 |
| 2019-12-03 | Incyte Corporation | $1,295 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-12-03 | Incyte Corporation | $1,295 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-12-03 | Incyte Corporation | $1,295 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-12-03 | Incyte Corporation | $1,295 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-12-03 | Incyte Corporation | $1,295 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-12-03 | Incyte Corporation | $1,295 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-12-03 | Incyte Corporation | $1,295 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 |
The latest 200 records of 3,184.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Birmingham, AL, county Jefferson County, AL, state Alabama; placed by its city name.
| Measure | Place (city or town) Birmingham, AL | County Jefferson County, AL | State Alabama |
|---|---|---|---|
| Population B01003 | 198,173 | 667,755 | 5,086,768 |
| Population, 2020 census P1 | 200,733 | 674,721 | 5,024,279 |
| Median age B01002 | 35.6 | 37.7 | 39.3 |
| Under 18 B01001 | 18.9% | 22.9% | 22.2% |
| 65 and over B01001 | 16.4% | 16.8% | 17.8% |
| Households B11001 | 88,788 | 269,883 | 1,997,247 |
| Foreign born B05002 | 4.7% | 4.9% | 4.0% |
| Median household income B19013 | $46,051 | $66,388 | $63,999 |
| Median family income B19113 | $58,445 | $87,393 | $83,032 |
| Per capita income B19301 | $32,216 | $41,013 | $36,087 |
| Poverty rate B17001 | 24.7% | 15.7% | 15.6% |
| Unemployment rate B23025 | 5.8% | 4.7% | 4.7% |
| Civilian labor force B23025 | 97,490 | 326,550 | 2,367,787 |
| Mean commute (minutes) B08013 | 20.8 | 24.1 | 25.5 |
| Bachelor's degree or higher B15003 | 31.1% | 36.2% | 28.4% |
| Housing units B25001 | 109,349 | 310,789 | 2,337,265 |
| Owner-occupied B25003 | 45.5% | 63.9% | 70.2% |
| Renters B25003 | 54.5% | 36.1% | 29.8% |
| Median home value B25077 | $158,800 | $240,000 | $209,900 |
| Median gross rent B25064 | $1,107 | $1,193 | $1,007 |
| White, not Hispanic B03002 | 24.2% | 47.5% | 63.4% |
| Black B03002 | 66.7% | 42.1% | 25.6% |
| Hispanic or Latino B03002 | 4.8% | 5.5% | 5.6% |
| Asian B03002 | 1.4% | 1.9% | 1.4% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.3% |
Economy now FRED unemployment 3.5% in Sep 2026 (2.8% a year earlier); per capita personal income $59,754 in 2025, up 30% in five years (+4.7% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Birmingham, AL.
Comments